Denesh Chitkara
About Denesh Chitkara
Denesh Chitkara is the Executive Director/Clinical Development Team Lead at Bristol Myers Squibb, specializing in GI, Cendakimab, fibrosis, and COVID-19 therapies.
Company
Denesh Chitkara is currently employed at Bristol Myers Squibb, where he serves as the Executive Director and Clinical Development Team Lead for gastrointestinal immunology, Cendakimab, fibrosis, and COVID-19 Duo. Bristol Myers Squibb is a globally recognized biopharmaceutical company renowned for its focus on innovative medicines.
Title
At Bristol Myers Squibb, Denesh Chitkara holds the title of Executive Director and Clinical Development Team Lead in multiple key areas including gastrointestinal immunology, Cendakimab, fibrosis, and COVID-19 Duo. His role encompasses leading and managing clinical development initiatives aimed at innovative treatment solutions.
Previous Industry Roles
Before joining Bristol Myers Squibb, Denesh Chitkara served as Executive Director of Clinical Research at Celgene from 2018 to 2019, and Senior Director of Clinical Research from 2014 to 2018, working on innovative therapies. Prior to these roles, he was Director of Clinical Research at Merck from 2007 to 2014, contributing to significant clinical development projects.
Academic Background
Denesh Chitkara has a notable academic background in pediatrics. He worked at the University of North Carolina at Chapel Hill as an Assistant Professor of Pediatrics from 2005 to 2007, Boston Children's Hospital as an Instructor of Pediatrics from 2003 to 2005, and Mayo Clinic as an Instructor of Pediatrics in 2003. He has an MD in Medicine from The Ohio State University College of Medicine, which he earned from 1992 to 1996.
Expertise in Clinical Research
With over two decades of experience, Denesh Chitkara has extensive expertise in the field of clinical research and development. His work spans gastrointestinal immunology, fibrosis, and COVID-19 therapeutic developments. He has been leading clinical development efforts for Cendakimab, a monoclonal antibody targeting interleukin-13, since November 2021.